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Comparative effectiveness of diet alone and diet  
plus metformin treatment on omentin levels in type  
2 diabetes patients with nonalcoholic fatty liver  
disease: a prospective randomized trial
Abstract
Aim: The aim of this study was to compare the effectiveness of diet alone 
and diet plus metformin treatment on omentin levels in type 2 diabetes 
patients with nonalcoholic fatty liver disease.
Methods: Consecutively 88 patients who had hepatic steatosis with type-
2 DM were recruited for the study. For randomization, 28 patients who 
had exclusion criteria were excluded from the study. The remaining patients 
(n = 60) were randomized into two groups. Only diet therapy were given 
to Group 1(n = 30) and metformin 2 gram/day plus diet were given to group 
2 (n = 30) during 3 months. During the follow-up period 5 patients in 
group 1 and 1 patient in group 2 did not come for follow-up. Therefore we 
evaluated 25 patients in group 1 and 29 patients in group 2. Omentin 
levels were analyzed at admission and at the end of the study.
Results: There was a statistically significant difference in the values of 
body weight, body mass index, waist and hip circumference, body fat per-
centage (%), and omentin in group 1; and in the values of body weight, 
BMI, waist and hip circumference, body fat percentage (%), and omentin 
in group 2. Omentin levels were significantly decreased with the treatment 
in both groups (5.37 ± 1.31 ng/ml to 4.00 ± 1.46 ng/ml in group 1; 6.96 
± 2.10 ng/ml to 3.92 ± 0.89 ng/ml in group 2, p = 0.001 respectively). 
When compared the percentage of changes between two groups, it was found 
that the omentin value was more decreased in group 2 (p = 0.032).
Conclusions: Although diet and diet plus metformin treatment de-
creased the omentin levels, diet plus metformin treatment would be more 
beneficial in type 2 diabetes patients with nonalcoholic fatty liver disease.
1. IntroductIon
Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis to nonalcoholic steatohepatitis and liver cirrhosis. NAFLD 
is often associated with metabolic syndrome elements such as obesity, 
hyperlipidemia, type 2 diabetes, and insulin resistance (1-3). The key 
role of insulin resistance in the course of NAFLD has been shown in 
several studies. Eliminating of insulin resistance can prevent the devel-
opment of NAFLD (4-6).
Metformin is an oral antidiabetics that shows the lowering effect on 








1  Harran University, Faculty of Medicine
Department of Internal Medicine, Sanliurfa/Turkey
2  Akdeniz University, Faculty of Medicine
Department of Internal Medicine, Antalya/Turkey
3  Harran University School of Medicine




Keywords: Nonalcoholic fatty liver disease, omentin, 
type 2 diabetes mellitus
Received April 30, 2016. 
Revised February 4, 2017. 
Accepted February 9, 2017.
Ibrahim Arslan et al. Nonalcoholic fatty liver disease & type 2 diabetes & treatment
10 Period biol, Vol 119, No 1, 2017.
increase in insulin-dependent glucose uptake in skeletal 
muscle. It reduces the fatty acid oxidation in muscles and 
liver, and also shows positive effects on plasma lipid profile 
by reducing low-density lipoprotein cholesterol and very 
low density lipoprotein cholesterol (7). Omentin released 
from the visceral adipose tissue increases the activity of 
insulin in glucose metabolism and transport of glucose 
stimulated by insulin in subcutaneous adipocytes as well 
as in omental adipocytes. It was reported that serum 
omentin levels have decreased in obesity and insulin re-
sistance (8, 9). Omentin gene expression has been de-
creased in obesity; decreased plasma omentin levels have 
been associated with increased obesity and insulin resis-
tance (10).
Although omentin levels were found to be lower in 
patients with steatohepatitis, no research study has been 
performed to evaluate the effect of metformin therapy on 
omentin levels. Therefore, the purpose of this study is to 
examine the omentin levels in type 2 diabetic patients 
with hepatic steatosis and to compare the effects of diet 
and the diet plus metformin treatment on omentin levels.
2. MAterIAls And Methods
This prospective cohort study was conducted at the 
Harran University School of Medicine, Sanliurfa, Turkey. 
Prior to subject recruitment, the study protocol was re-
viewed and approved by the local ethics committee, in 
accordance with the ethical principles for human investi-
gations, as outlined by the Second Declaration of Hel-
sinki, and written informed consent was obtained from all 
the patients. Consecutively 88 patients who had hepatic 
steatosis with type-2 DM were recruited for the study.
The exclusion criteria were as follows: pregnancy; pa-
tients should be started insulin or insulin secretagogue; 
patients with contraindication to initiation of metformin; 
diabetic ketoacidosis; acute or chronic metabolic acidosis; 
renal failure; congestive heart failure; chronic liver dis-
ease; recent myocardial infarction; acute or chronic alco-
holism; hypoxemia; and those against hypersensitivity to 
any component of the medication.
88 consecutive T2D patients with hepatic steatosis 
were recruited. Per protocol, 28 patients were excluded 
from the study. The remaining 60 patients were random-
ized into two groups. Group 1 (n=30) was assigned to diet 
alone; group 2 (n=30) received diet + metformin for 3 
months. 5 patients in group 1 and 1 patient in group 2 
were lost to follow-up, accordingly, 25 patients in group 
1 and 29 patients in group 2 were evaluated (Figure 1).
The diagnosis of diabetes mellitus was based on the 
American Diabetes Association 2012 criteria and on a 
previous history of diabetes (anti-diabetic medications 
usage), and NAFLD was diagnosed according to hepato-
biliary ultrasound findings. Ultrasound findings for 
NAFLD were a diffuse hyperechoic echotexture (bright 
liver), increased liver echotexture compared with the kid-
neys, vascular blurring, and deep attenuation (11, 12).
Height and weight were measured according to stan-
dard protocols. Body mass index (BMI) was calculated as 
the person’s weight in kilograms divided by his or her 
height in meters squared (kg/m2). Body compositions 
were assessed with bioelectrical impedance analysis (BF 
510, Omron Healthcare Co. Ltd., Kyoto, Japan). HOMA-
IR was used to evaluate insulin sensitivity of patients. 
HOMA-IR was calculated by the formula: [fasting serum 
glucose (mg / dl) x fasting serum insulin (μıU / ml)] / 405. 
Other biochemical analyses were determined using com-
mercially available assay kits (Abbott, Abbott Park, USA) 
with an auto-analyzer (Abbott, Abbott Park, USA).
At the beginning and end of the study, 7 ml of venous 
blood samples were taken from each patient to analyze 
omentin levels and were placed in biochemistry tubes. 
Venous blood samples were separated serums after cen-
trifugation at 3500 rpm for 10 minutes and serum sam-
ples were immediately stored at -80 °C until working time 
by putting into a special box. Serum omentin-1 levels were 
determined using an omentin-1 Enzyme Linked Immuno 
Sorbent Assay (ELISA; BioVendor Laboratorni medicina, 
Brno, Czech Republic). The results were formed in ac-
cordance with quality control serums and controls and 
were calculated according to the calibration curve. Omen-
tin levels are referred in ng / mL.
All statistical analyses were performed using SPSS 20.0 
for Windows (SPSS, Chicago, IL, USA). Kolmogorov-
Smirnov tests were used to test the normality of the data 
distribution. The data were expressed as the mean and 
standard deviation. The chi-square test was used to com-
pare the categorical variables between groups. Independent 
Sample T test and Mann-Whitney U tests were used for 
normally and nonnormally distributed continuous data, 
respectively. Paired t-test and Wilcoxon signed-rank tests 
were used to analyze changes in each group. A two-sided 
p value < 0.05 was considered to be statistically significant.
Figure 1. Consort diagram of the participants
Nonalcoholic fatty liver disease & type 2 diabetes & treatment Ibrahim Arslan et al.
Period biol, Vol 119, No 1, 2017. 11
results
The demographic, anthropometric and laboratory pa-
rameters of both groups before treatment are shown in 
Table 1. There was no statistically significant difference 
in terms of clinical and demographic data between the 
two groups. When considered the effect of treatment; 
there was a statistically significant difference in the values 
of body weight, BMI, waist and hip circumference, body 
fat percentage (%), HOMA-IR, HbA1c, glucose and 
omentin in group 1, and in the values of body weight, 
BMI, waist and hip circumference, body fat percentage 
(%), HOMA-IR, glucose, triglycerides, and omentin in 
group 2 (Table 2, 3).
Omentin levels were significantly decreased with the 
treatment in both groups (5.37 ± 1.31 ng/ml to 4.00 ± 
1.46 ng/ml in group 1; 6.96 ± 2.10 ng/ml to 3.92 ± 0.89 
ng/ml in group 2, p = 0.001 respectively) (Figure 2). 
When compared the percentage of change between two 
groups, it was found that the omentin value was more 
decreased in group 2 (p = 0.032) (Figure 3).
Table 1. Demographic, anthropometric and laboratory features of the groups before treatment
Parameter Diet group
N=25
Diet plus metformin group
N=29
P value
Age (years) 38.36±10.14 39.53±10.58 NS
Gender (M / F) 12/13 15/14 NS
Body Weight (kg) 86.86±11.55 90.94±15.82 0.291
BMI (kg / m²) 33.08±4.86 34.19±5.73 NS
Waist circumference (cm) 107.48±9.34 106.72±10.63 NS
Hip circumference (cm) 111.80±10.25 112.89±12.39 NS
Body fat percentage (%) 38.36±10.14 39.53±10.58 NS
Glucose (mg / dl) 132.48±35.93 140.24±42.12 NS
Creatinine (mg / dl) 0.74±0.12 0.76±0.22 NS
AST (U / L) 28.40±25.18 32.34±21.34 0.027
ALT (U / L) 34.84±34.13 45.68±38.25 0.046
GGT (U / L) 46.04±70.44 47.06±28.74 NS
Total Cholesterol (mg / dl) 217.04±43.97 198.68±39.81 NS
LDL-Cholesterol (mg / dl) 132.44±40.41 114.37±32.89 0.076
HDL-Cholesterol (mg / dl) 41.64±9.12 43.44±10.65 NS
Triglycerides (mg / dl) 211.28±107.75 207.58±122.90 NS
HbA1c (%) 6.36±0.67 6.55±0.52 NS
HOMA-IR 6.54±4.78 6.52±3.92 NS
Omentin (ng/mL) 5.37±1.31 6.96±2.10 0.002
Variables were expressed as mean ± standard deviations. NS: Not significant; BMI: Body Mass Index; AST: aspartate transaminase; ALT: alanine 
transaminase; GGT: gamma-glutamyl transferase; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HbA1c: 
glycated haemoglobin; HOMA-IR: homeostasis model assessment of insulin resistance
Table 2. Anthropometric and laboratory values before and after treatment in Diet group
Parameter Before treatment After treatment P value
Body Weight (kg) 86.86±11.55 84.45±11.19 0.001
BMI (kg / m²) 33.08±4.86 32.15±5.12 0.001
Waist circumference (cm) 107.48±9.34 105.08±9.01 0.002
Hip circumference (cm) 111.80±10.25 109.08±9.90 0.001
Body fat percentage (%) 38.36±10.14 35.60±9.57 0.008
Glucose (mg / dl) 132.48±35.93 116.20±28.10 0.008
Total Cholesterol (mg / dl) 217.04±43.97 204.96±45.82 NS
LDL-Cholesterol (mg / dl) 132.44±40.41 128.28±45.26 NS
HDL-Cholesterol (mg / dl) 41.64±9.12 40.88±7.04 NS
Triglycerides (mg / dl) 211.28±107.75 177.40±78.27 NS
Hba1c (%) 6.36±0.67 6.15±0.53 0.027
HOMA-IR 6.54±4.78 3.49±3.37 <0.001
Omentin (ng / ml) 5.37±1.31 4.00±1.46 0.001
Variables were expressed as mean ± standard deviations. NS: Not significant; BMI: Body Mass Index; LDL-C: low-density lipoprotein cholesterol; 
HDL-C: high-density lipoprotein cholesterol; HbA1c: glycated haemoglobin; HOMA-IR: homeostasis model assessment of insulin resistance
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dIscussIon
To the best of our knowledge, this is the first showing 
the effect of metformin therapy on body weight and the 
omentin level in type 2 diabetes mellitus patients with 
NAFLD.
Insulin resistance is the major factors behind the altera-
tions of uptake, synthesis, degradation, and secretion of 
free fatty acids in the liver which leads to accumulation of 
lipids that cause the NAFLD (13). It has been shown that 
insulin resistance and fatty acid metabolism improved after 
significant weight loss (14, 15). Additionally, there are 
many studies reporting that losing weight provide improve-
ment of histology (16, 17). Metformin is a first-line oral 
anti-hyperglycemic that improves insulin sensitivity in the 
liver and skeletal muscle (18). Metformin is not caused 
Table 3: Anthropometric and laboratory values before and after treatment in Diet plus metformin group
Parameter Before treatment After treatment P value
Body Weight (kg) 90.94±15.82 87.79±15.37 <0.001
BMI (kg / m²) 34.19±5.73 32.99±5.70 <0.001
Waist circumference (cm) 106.72±10.63 100.89±16.74 0.036
Hip circumference (cm) 112.89±12.39 109.41±12.40 <0.001
Body fat percentage (%) 39.53±10.58 36.01±10.22 <0.001
Glucose (mg / dl) 140.24±42.12 123.51±32.17 0.038
Total Cholesterol (mg / dl) 198.68±39.81 189.68±37.06 NS
LDL-Cholesterol (mg / dl) 114.37±32.89 114.24±34.22 NS
HDL-Cholesterol (mg / dl) 43.44±10.65 41.86±8.67 NS
Triglycerides (mg / dl) 207.58±122.90 170.82±91.50 0.034
Hba1c (%) 6.55±0.52 6.24±0.24 NS
HOMA-IR 6.52±3.92 4.00±3.80 0.001
Omentin (ng / ml) 6.96±2.10 3.92±0.89 <0.001
Variables were expressed as mean ± standard deviations. NS: Not significant; BMI: Body Mass Index; LDL-C: low-density lipoprotein cholesterol; 
HDL-C: high-density lipoprotein cholesterol; HbA1c: glycated haemoglobin; HOMA-IR: homeostasis model assessment of insulin resistance
Figure 2: Graph demonstrating the pre-treatment and post-treatment omentin values both in groups
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weight gain and, in fact, it has been shown to induce mod-
est weight loss (19-22). We detected that metformin did 
not provide additional impact to the weight-loss effect of 
diet therapy in diabetic patients with NAFLD.
It has been shown that omentin levels are increased in 
obese subjects after weight loss (23). Reduced omentin lev-
els in patients with diabetes are also observed (24, 25). In-
terestingly, Yılmaz et al. showed that serum omentin levels 
are raised in patients with NAFLD, omentin levels are 
positively associated with hepatocyte ballooning –indicator 
of hepatocyte degeneration- independent of insulin resis-
tance and some features of the metabolic syndrome (26). 
They also hypothesized that omentin might play a role in 
the development and progression of NAFLD. We detected 
that omentin levels are increased with loss of weight con-
trary to literature. NAFLD may be a confounder; so that, 
we suggest additional studies to identify reasons for this 
paradoxical increase as proposition of Yılmaz et al. (26).
Studies concluded that metformin did not improve 
findings of liver histology included steatosis, lobular in-
flammation, hepatocellular ballooning and fibrosis in 
NAFLD (27). Other studies demonstrated that metfor-
min treatment decreased omentin levels in diabetes and 
polycystic ovary syndrome (28, 29). However, Estegha-
mati et al. found that both insulin sensitizers -metformin 
and pioglitazone- are decresed serum omentin concentra-
tions in diabetic patients (30). In another study, Kim et 
al. found that metformin enhanced insulin sensitivity via 
independent mechanisms from phosphatidylinositol 3-ki-
nase activity (31). Estagmati et al. hypothesized that after 
restored of insulin sensitivity, Akt signaling and its up-
stream mediators such as omentin might be suppressed. 
Therefore, insulin sensitizers paradoxically inhibit the 
omentin by this negative feedback mechanism (32). Our 
similar results may be explained by this way.
When all of these data taken into account, metformin 
seem to not to provide additional benefits compared to 
weight loss. At present guidelines, metformin is not rec-
ommended as a primary treatment especially from the 
standpoint of nonalcoholic steatohepatitis (33). We can 
also say that it can be used in diabetic patients with 
NAFLD for other indications as recommended previ-
ously (34). Furthermore, the interactions of insulin sen-
sitizers and NAFLD with omentin levels must be an-
swered by further study.
The most important limitation of our study is the lack 
of enough patients and healthy control group. The com-
parison of omentin levels of diabetic patients with 
NAFLD and healthy individuals can provide new infor-
mation to the literature. Another limitation of our study 
is the randomly higher omentin levels of diet plus metfor-
min group at the beginning of study.
In conclusion, although the effects of diet and diet plus 
metformin treatment on BMI of our results are consistent 
with the literature, but their effects on the omentin level 
is inconsistent. The important of omentin in the course 
of NAFLD remain unknown. Altogether, our study adds 
to the current evidence suggesting that omentin may have 
unusual role in the diabetics with NAFLD. Therefore, 
these observations have to be replicated in larger, better 
randomized trials with comparison of healthy individuals.
Conflict of interest: None declared
Figure 3: Graph demonstrating the percentage change of the omentin values both in two groups
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